AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05372614
Drug: Neratinib Maleate
RxNorm normalized name: Neratinib Maleate
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05621668
Drug: attIL2-T cells
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT00002197
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04867837
Drug: Octaplex
DrugBank: Prothrombin (DB11311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-factor prothrombin complex concentrate (4F-PCC)
Trial: NCT05627362
Drug: Elafibranor 80 mg
RxNorm normalized name: elafibranor 80 MG
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05627362
Drug: Elafibranor 120 mg
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05627362
Drug: Placebo Matched to Elafibranor 80 mg
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05627362
Drug: Placebo Matched to Elafibranor 120 mg
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04882098
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive guselkumab as SC injection.
Trial: NCT05804526
Drug: RC88
RxNorm normalized name: RC88
DrugBank: RC88 (DB18697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
Trial: NCT05804526
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
Trial: NCT05478720
Drug: 6-diazo-5-oxo-L-norleucine (DON)
RxNorm normalized name: 6-ammonio-L-norleucine
DrugBank: 6-diazo-5-oxo-L-norleucine (DB17537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose
Trial: NCT05478720
Drug: 6-diazo-5-oxo-L-norleucine (DON)
RxNorm normalized name: 6-ammonio-L-norleucine
DrugBank: 6-diazo-5-oxo-L-norleucine (DB17537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
Trial: NCT05065164
Drug: Denosumab Only Product
RxNorm normalized name: Denosumab only product
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: denosumab subcutaneous injection /6 months, twice a year
Trial: NCT04269902
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05099003
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT06041503
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
Trial: NCT06041503
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
Trial: NCT06678659
Drug: REC-1245
RxNorm normalized name: REC-994
DrugBank: REC-994 (DB15616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REC-1245 capsule 1mg, 5mg, 25mg
Trial: NCT06676033
Drug: epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Trial: NCT05286788
Drug: Binimetinib Oral Tablet [Mektovi]
RxNorm normalized name: binimetinib Oral Tablet [Mektovi]
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
Trial: NCT06423859
Drug: Articaine
RxNorm normalized name: Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: supraclavicular brachial plexus block with articaine 2%
Trial: NCT06423859
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
Trial: NCT06325709
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
Trial: NCT06325709
Drug: Palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
Trial: NCT06325709
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
Trial: NCT06325709
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
Trial: NCT06694454
Drug: azacytidine
RxNorm normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.
Trial: NCT06694454
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT06694454
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT06694454
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT06694454
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT06694454
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT06694454
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Trial: NCT05996627
Drug: Belumosudil
RxNorm normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05664893
Drug: Ribociclib Oral Tablet
RxNorm normalized name: ribociclib Oral Tablet
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance
Trial: NCT06247488
Drug: Oxycodone 20 mg
RxNorm normalized name: oxycodone 20 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive oral dose of oxycodone 20 mg.
Trial: NCT06247488
Drug: GE-IR 200 mg
RxNorm normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
Trial: NCT06247488
Drug: GE-IR 450 mg
RxNorm normalized name: 18F-GE-180
DrugBank: Flutriciclamide F-18 (DB15380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
Trial: NCT05672173
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05672173
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06083883
Drug: Fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06226571
Drug: SNDX-5613
RxNorm normalized name: anti-Csf1R monoclonal antibody SNDX-6352
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
Trial: NCT06045975
Drug: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions.
Trial: NCT05255484
Drug: LM-108
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05255484
Drug: An Anti-PD-1 Antibody
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT06475196
Drug: Sintilimab (PD-1 inhibitor)
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
Trial: NCT05470881
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of one drop QD on both eyes for 14 days.
Trial: NCT05328297
Drug: JNJ-55308942
RxNorm normalized name: JNJ-55308942
DrugBank: JNJ-55308942 (DB19110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-55308942 capsules will be administered orally.
Trial: NCT06213649
Drug: Polyhexamethylene biguanide (PHMB)
DrugBank: Polihexanide (DB12277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
Trial: NCT05411718
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05382390
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Trial: NCT05382390
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Trial: NCT06233045
Drug: Dapagliflozin-Test product
RxNorm normalized name: dapagliflozin Oral Product
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
Trial: NCT06233045
Drug: Dapagliflozin-Reference product
RxNorm normalized name: dapagliflozin Oral Product
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
Trial: NCT00347802
Drug: Bimatoprost 0.03%, Travoprost 0.004%
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06236139
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06236139
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04963439
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
Trial: NCT04750928
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
Trial: NCT04944290
Drug: Brinzolamide/brimonidine ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test product
Trial: NCT06275542
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
Trial: NCT05047172
Drug: Ticagrelor + Aspirin
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
Trial: NCT05047172
Drug: Rivaroxaban + Aspirin
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
Trial: NCT05047172
Drug: Clopidogrel + Aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
Trial: NCT05107999
Drug: Doxepin Hydrochloride (Doxepin)
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FD patients were treated with doxepin and omeprazole for 4 weeks.
Trial: NCT05683171
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05683171
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT05683171
Drug: Valemetostat
RxNorm normalized name: Valemetostat
DrugBank: Valemetostat (DB18314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06120881
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
Trial: NCT06406465
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status
Trial: NCT06406465
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 IV over 60 minutes on day 2
Trial: NCT06406465
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
Trial: NCT04607837
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Trial: NCT06719596
Drug: Bifidobacterium Bifidum Oral Capsule
RxNorm normalized name: Bifidobacterium Bifidum Oral Capsule
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
Trial: NCT06721039
Drug: Bilateral QL block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes
Trial: NCT06721039
Drug: Intraperitoneal and port sites infiltration
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
Trial: NCT06721052
Drug: meta-Peng block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.
Trial: NCT06785012
Drug: JNJ-89495120
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-89495120 will be administered.
Trial: NCT03127618
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06132113
Drug: BI 764532
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764532
Trial: NCT06132113
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care
Trial: NCT06132113
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care
Trial: NCT06132113
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT02531880
Drug: Mangafodipir
RxNorm normalized name: Mangafodipir
DrugBank: Mangafodipir (DB06796)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.